Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.

Kaposi sarcoma-associated (KS-associated) herpesvirus (KSHV) infection is linked to the development of both KS and several lymphoproliferative diseases. In all cases, the resulting tumor cells predominantly display latent viral infection. KS tumorigenesis requires ongoing lytic viral replication as well, however, for reasons that are unclear but have been suggested to involve the production of angiogenic or mitogenic factors by lytically infected cells. Here we demonstrate that proliferating cells infected with KSHV in vitro display a marked propensity to segregate latent viral genomes, with only a variable but small subpopulation being capable of stable episome maintenance. Stable maintenance is not due to the enhanced production of viral or host trans-acting factors, but is associated with cis-acting, epigenetic changes in the viral chromosome. These results indicate that acquisition of stable KSHV latency is a multistep process that proceeds with varying degrees of efficiency in different cell types. They also suggest an additional role for lytic replication in sustaining KS tumorigenesis: namely, the recruitment of new cells to latency to replace those that have segregated the viral episome.

[1]  D. Ganem,et al.  Host Range of Kaposi's Sarcoma-Associated Herpesvirus in Cultured Cells , 2003, Journal of Virology.

[2]  Frederick Y. Wu,et al.  A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma–associated herpesvirus latency , 2003, Nature Medicine.

[3]  D. Ganem,et al.  The Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Permits Replication of Terminal Repeat-Containing Plasmids , 2003, Journal of Virology.

[4]  Jianhong Hu,et al.  The Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Supports Latent DNA Replication in Dividing Cells , 2002, Journal of Virology.

[5]  C. Lim,et al.  Functional Dissection of Latency-Associated Nuclear Antigen 1 of Kaposi's Sarcoma-Associated Herpesvirus Involved in Latent DNA Replication and Transcription of Terminal Repeats of the Viral Genome , 2002, Journal of Virology.

[6]  Jianhong Hu,et al.  Latency-associated Nuclear Antigen (LANA) Cooperatively Binds to Two Sites within the Terminal Repeat, and Both Sites Contribute to the Ability of LANA to Suppress Transcription and to Facilitate DNA Replication* , 2002, The Journal of Biological Chemistry.

[7]  P. Stewart,et al.  Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. , 2002, The Journal of infectious diseases.

[8]  Shou-Jiang Gao,et al.  Efficient Infection by a Recombinant Kaposi's Sarcoma-Associated Herpesvirus Cloned in a Bacterial Artificial Chromosome: Application for Genetic Analysis , 2002, Journal of Virology.

[9]  M. McMahon,et al.  De Novo Infection and Serial Transmission of Kaposi's Sarcoma-Associated Herpesvirus in Cultured Endothelial Cells , 2002, Journal of Virology.

[10]  T. Tlsty,et al.  Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. , 2002, Experimental cell research.

[11]  E. Robertson,et al.  The Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen binds to specific sequences at the left end of the viral genome through its carboxy-terminus. , 2001, Virology.

[12]  Hong Li,et al.  Human Herpesvirus 8 (HHV-8)-Encoded Cytokines Induce Expression of and Autocrine Signaling by Vascular Endothelial Growth Factor (VEGF) in HHV-8-Infected Primary-Effusion Lymphoma Cell Lines and Mediate VEGF-Independent Antiapoptotic Effects , 2001, Journal of Virology.

[13]  Jianhong Hu,et al.  DNA Binding and Modulation of Gene Expression by the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus , 2001, Journal of Virology.

[14]  B. Sugden,et al.  Establishment of an oriP Replicon Is Dependent upon an Infrequent, Epigenetic Event , 2001, Molecular and Cellular Biology.

[15]  Frederick Y. Wu,et al.  Spindle Cell Conversion by Kaposi's Sarcoma-Associated Herpesvirus: Formation of Colonies and Plaques with Mixed Lytic and Latent Gene Expression in Infected Primary Dermal Microvascular Endothelial Cell Cultures , 2001, Journal of Virology.

[16]  T. Piolot,et al.  Close but Distinct Regions of Human Herpesvirus 8 Latency-Associated Nuclear Antigen 1 Are Responsible for Nuclear Targeting and Binding to Human Mitotic Chromosomes , 2001, Journal of Virology.

[17]  M. Ballestas,et al.  Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 Mediates Episome Persistence through cis-Acting Terminal Repeat (TR) Sequence and Specifically Binds TR DNA , 2001, Journal of Virology.

[18]  A. Burlingame,et al.  Kaposi's Sarcoma-Associated Herpesvirus K-bZIP Protein Is Phosphorylated by Cyclin-Dependent Kinases , 2001, Journal of Virology.

[19]  P. Moore,et al.  Kaposi's Sarcoma-Associated Herpesvirus LANA2 Is a B-Cell-Specific Latent Viral Protein That Inhibits p53 , 2001, Journal of Virology.

[20]  P. Brown,et al.  Modulation of Cellular and Viral Gene Expression by the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus , 2001, Journal of Virology.

[21]  D. Ganem,et al.  The biology of Kaposi's sarcoma. , 2001, Cancer treatment and research.

[22]  J. Fallon,et al.  The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. , 2001, Blood.

[23]  D. Thorley-Lawson,et al.  The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. , 2000, Immunity.

[24]  R. Schooley,et al.  Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage , 2000, AIDS.

[25]  J. Routy,et al.  Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS Patients on highly active antiretroviral therapy , 2000, AIDS.

[26]  D. Noonan,et al.  Distinct chemotactic and angiogenic activities of peptides derived from Kaposi's sarcoma virus encoded chemokines. , 2000, International journal of oncology.

[27]  J. Levy,et al.  The restricted cellular host range of human herpesvirus 8 , 2000, AIDS.

[28]  C. Buchrieser,et al.  Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. , 2000, Journal of the National Cancer Institute.

[29]  C. Boshoff,et al.  KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. , 2000, Blood.

[30]  E. Cesarman,et al.  Viral G Protein–Coupled Receptor and Kaposi's Sarcoma , 2000, The Journal of experimental medicine.

[31]  Tong-Yuan Yang,et al.  Transgenic Expression of the Chemokine Receptor Encoded by Human Herpesvirus 8 Induces an Angioproliferative Disease Resembling Kaposi's Sarcoma , 2000, The Journal of experimental medicine.

[32]  G. Nabel,et al.  p53 inhibition by the LANA protein of KSHV protects against cell death , 1999, Nature.

[33]  E. Robertson,et al.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. , 1999, Virology.

[34]  S. Cheung,et al.  Nasopharyngeal carcinoma cell line (C666‐1) consistently harbouring Epstein‐Barr virus , 1999, International journal of cancer.

[35]  D. Thorley-Lawson,et al.  A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. , 1999, Life sciences.

[36]  R. Freeman,et al.  Epstein-Barr Virus–Infected Resting Memory B Cells, Not Proliferating Lymphoblasts, Accumulate in the Peripheral Blood of Immunosuppressed Patients , 1999, The Journal of experimental medicine.

[37]  A. Haase,et al.  Expression of the Open Reading Frame 74 (G-Protein-Coupled Receptor) Gene of Kaposi’s Sarcoma (KS)-Associated Herpesvirus: Implications for KS Pathogenesis , 1999, Journal of Virology.

[38]  M. Ballestas,et al.  Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. , 1999, Science.

[39]  E. van Marck,et al.  Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Palestine,et al.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. , 1999, The New England journal of medicine.

[41]  P. Allavena,et al.  The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. , 1998, Blood.

[42]  Bin Yang,et al.  Identification of the Site of Epstein-Barr Virus Persistence In Vivo as a Resting B Cell , 1998, Journal of Virology.

[43]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[44]  B. Nathwani,et al.  Evidence for multiclonality in multicentric Kaposi's sarcoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Ganem,et al.  Limited Transmission of Kaposi’s Sarcoma-Associated Herpesvirus in Cultured Cells , 1998, Journal of Virology.

[46]  U. Arad Modified Hirt procedure for rapid purification of extrachromosomal DNA from mammalian cells. , 1998, BioTechniques.

[47]  E. Cesarman,et al.  Erratum: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.

[48]  B. Ensoli,et al.  Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. , 1998, Cytokine & growth factor reviews.

[49]  S. Cheung,et al.  Characterization of a new EBV-associated nasopharyngeal carcinoma cell line. , 1998, Cancer genetics and cytogenetics.

[50]  E. Cesarman,et al.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.

[51]  C. Boshoff,et al.  Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. , 1997, Science.

[52]  D. Ganem,et al.  The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus. , 1997, Virology.

[53]  É. Oksenhendler,et al.  Molecular analysis of clonality in Kaposi's sarcoma. , 1997, Journal of clinical pathology.

[54]  G. Millot,et al.  Characterization of in vitro culture of HIV-negative Kaposi’s sarcoma-derived cells. In vitro responses to alfa interferon , 1997, Archives of Dermatological Research.

[55]  K. Jeang,et al.  Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy , 1997, AIDS.

[56]  F. Neipel,et al.  Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin , 1997, Journal of virology.

[57]  A. Haase,et al.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells , 1997, Journal of virology.

[58]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma , 1996, Journal of virology.

[59]  R. Gallo,et al.  Absence of human herpesvirus 8 DNA sequences in neoplastic Kaposi's sarcoma cell lines. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[60]  D. Noonan,et al.  KSHV sequences in biopsies and cultured spindle cells of epidemic, iatrogenic and Mediterranean forms of Kaposi's sarcoma. , 1996, Research in virology.

[61]  C. Boshoff,et al.  Cyclin encoded by KS herpesvirus , 1996, Nature.

[62]  N. Bendsøe,et al.  Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients. , 1996, The American journal of pathology.

[63]  M. McGrath,et al.  Lytic growth of Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) in culture , 1996, Nature Medicine.

[64]  B. Ensoli,et al.  Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. , 1995, The Journal of clinical investigation.

[65]  M. Raffeld,et al.  Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. , 1994, The Journal of clinical investigation.

[66]  J. Levy,et al.  Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals , 1994, AIDS.

[67]  J. Corbeil,et al.  Culture and properties of cells derived from Kaposi sarcoma. , 1991, Journal of immunology.

[68]  R. Auerbach,et al.  A hemangioendothelioma-derived cell line: its use as a model for the study of endothelial cell biology. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[69]  S. Nakamura,et al.  AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. , 1989, Science.

[70]  S. Nakamura,et al.  Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. , 1988, Science.

[71]  T. Gardella,et al.  Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis , 1984, Journal of virology.